Abstract
We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.
| Original language | English |
|---|---|
| Pages (from-to) | 1039-1043 |
| Number of pages | 5 |
| Journal | Oncology Reports |
| Volume | 22 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2009 |
Fingerprint
Keywords
- Adenovirus
- OBP-301
- Squamous cell carcinoma of the head and neck
- Telomelysin
- Telomerase
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer. / Nakajima, Oumi; Ichimaru, Daiju; Urata, Yasuo; Fujiwara, Toshiyoshi; Horibe, Tomohisa; Kohno, Masayuki; Kawakami, Koji.
In: Oncology Reports, Vol. 22, No. 5, 2009, p. 1039-1043.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Use of telomelysin (OBP-301) in mouse xenografts of human head and neck cancer
AU - Nakajima, Oumi
AU - Ichimaru, Daiju
AU - Urata, Yasuo
AU - Fujiwara, Toshiyoshi
AU - Horibe, Tomohisa
AU - Kohno, Masayuki
AU - Kawakami, Koji
PY - 2009
Y1 - 2009
N2 - We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.
AB - We previously reported that telomerase-specific replication-component adenovirous, Telomelysin (OBP-301) has cytotoxic activity to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro, and investigated the association between cytotoxic activity and adenoviral receptor expression. In this study, we evaluated the most appropriate way to administer telomelysin (OBP-301) in the treatment of squamous cell carcinoma of the head and neck (SCCHN), and assessed the effect of OBP-301 in large subcutaneous KCCT873 human SCCHN tumors in immunodeficient mice. We also compared antitumor responses following three intratumoral (i.t.) injections of OBP-301 given daily, every 2 days or weekly. To investigate the mechanism of the antitumor effect, we evaluated cellular infiltration in treated tumors. OBP-301 showed remarkable antitumor activity against large KCCT873 tumors, and three treatment schedules produced similar antitumor effects. The weekly regimen also significantly reduced the growth of large tumors. Immunochemistry revealed that macrophages, but not natural killer cells, were responsible for tumor regression. A regimen of three weekly injections of OBP-301 has remarkable antitumor effects against large KCCT873 tumors. These results may provide a new platform for treating patients with localized SCCHN.
KW - Adenovirus
KW - OBP-301
KW - Squamous cell carcinoma of the head and neck
KW - Telomelysin
KW - Telomerase
UR - http://www.scopus.com/inward/record.url?scp=70449448159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70449448159&partnerID=8YFLogxK
U2 - 10.3892/or_00000533
DO - 10.3892/or_00000533
M3 - Article
C2 - 19787218
AN - SCOPUS:70449448159
VL - 22
SP - 1039
EP - 1043
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 5
ER -